MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

64.08 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Revolution Medicines (RVMD) Earnings Transcript
Revolution Medicines (RVMD) Earnings Transcript 
Via The Motley Fool
Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement
Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers. 
Via Benzinga
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.
The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months. 
Via Investor's Business Daily
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
A Glimpse of Revolution Medicines's Earnings Potential
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Top 3 Health Care Stocks That Could Blast Off In December
 
Via Benzinga
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing... 
Via Benzinga
Topics Economy
Earnings Scheduled For November 5, 2025
 
Via Benzinga
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
'No Need To Sell' Martin Marietta Materials, Cramer Says: 'It's Just A Great Long-Term Hold'
Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a price target of $620. 
Via Benzinga
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks. 
Via Stocktwits
Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug
Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Aon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Revolution Medicines Inc (NASDAQ:RVMD) Reports Q2 2025 Earnings Miss, Shares Drop 4.5% After-Hours
Revolution Medicines (RVMD) missed Q2 2025 revenue and EPS estimates, reporting $0 revenue and a -$1.31 loss. Shares dropped 4.5% amid investor concerns, despite progress in Phase 3 trials for... 
Via Chartmill
Topics Earnings
This GitLab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch. 
Via Benzinga
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured... 
Via Stocktwits
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?
Revolution Medicines shared Phase 1 data showing zoldonrasib's acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025. 
Via Benzinga
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
 
Via Benzinga
Topics Stocks
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story